Executives-in-Residence & Advisors

“Every venture fund I’ve ever met has promised to add value beyond capital, but SignalFire is the first I’ve known to exceed all expectations.”*
All Companies































Recent posts

October 22, 2026
Drug discovery is limited by how fast humans can run experiments. Warp Sciences, which emerged from stealth today with $215 million, is building an automated U.S. chemistry lab that makes molecules for biopharma customers, and it uses every experiment to train AI that helps decide what to make next. Here’s why we invested.

August 11, 2026
SignalFire is doubling down on Flagler Health's $50M Series B. Learn how this AI-native MSK operating system is transforming musculoskeletal care for clinics.

February 10, 2026
SignalFire is doubling down on Solace’s $130 million Series C. Discover how Solace uses a full-stack OS and CMS reimbursement (CHI/PIN codes) to turn healthcare advocacy into essential infrastructure, achieving 10x YoY growth and a $1 billion+ valuation.
*Portfolio company founders listed above have not received any compensation for this feedback and may or may not have invested in a SignalFire fund. These founders may or may not serve as Affiliate Advisors, Retained Advisors, or consultants to provide their expertise on a formal or ad hoc basis. They are not employed by SignalFire and do not provide investment advisory services to clients on behalf of SignalFire. Please refer to our disclosures page for additional disclosures.



